Reports Q4 revenue $17.57M, consensus $3.36M. “As we enter 2024, we are financially strong, focused and motivated,” stated Dr. Neal Walker, co-founder and Interim Chief Executive Officer & President of Aclaris. “Returning to the CEO role, I look forward to building on our strong foundation and deep expertise in kinase discovery and development as we look to shape the future of Aclaris.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACRS:
- Aclaris Therapeutics Executive Team Undergoes Major Changes
- Aclaris Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Aclaris Therapeutics Announces Executive Leadership Changes
- Aclaris Therapeutics conducting strategic review of business
- Aclaris Therapeutics CEO Douglas Manion to step down
